List of Survey Items (2000-2017)

surveys were perfomed only by electric media from 2015 (paper media survey was abolished from 2015)

● survey items by both paper and electronic media
○ survey items only by electronic media

Facility Survey

Category	Sub	Item	00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17
infection control	hepatitis	zoning for viral hepatitis-related patients (y/n)								●										
	infection control	hospital/clinic infection control committee (y/n)								●										
number of workers involved in dialysis	number of workers involved in dialysis treatment	doctors, nurses, clinical engineers, nutritionists, case workers, others	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
dialysis fluid quality management	endotoxin (ET)	number of bedside consoles equipped with endotoxin retentive filter (ETRF)								●	●	●	●	●	●	●	●	●	●	●
		sampling site of dialysis fluid									●	●	●	●	●	●	●	●	●	
		use of ETRFs at sampling (y/n)									●	●	●	●	●	●	●	●	●	
		frequency of measuring ET								●	●	●	●	●	●	●	●	●	●	
		ET concentration (EU/mL)								●	●	●	●	●	●	●	●	●	●	
	total viable microbial count (TVC)	Frequency of measuring total viable microbial count (TVC) in dialysis fluid								●	●	●	●	●	●	●	●	●	●	
		TVC (cfu/mL)								●	●	●	●	●	●	●	●	●	●	
		cultivation medium for TVC								●	●	●	●	●	●	●	●	●	●	
		sampling volume for TVC(mL)								●	●	●	●	●	●	●	●	●		
	management for chemical pollution	source of dialysis water																		●
		frequency of testing residual chlorine before																		●
		method for testing residual chlorine																		●
		recognition about the JSDT standard for chemical contaminations of dialysis fluids																		●
		frequency of measurement of chemical water quality																		●

Patient Survey

Category	Sub	Item	00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17
management of dialysis	treatment modality, HDF	dialysis modality (HD/HDF/HF/Hemoperfusion/Home HD/PD)	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○
		combination therapy of HD(F) and PD (y/n)								●	●	●	●	●	●	●	●	○	○	○
		duration of present PD treatment (year)								●	●	●								
		duration of present PD treatment (month)													○	○	○	○	○	○
		history of PD treatment (y/n)											●	●	●	●	●	○	○	○
		number of past renal transplantations													●	●	●	○	○	○
		dilution mode of HDF (pre-/post-)													●	●	●	○	○	○
		substitution fluid volume per HDF session (L)													●	●	●	○	○	○
		reason for providing HDF														○				
	dialysis time and frequency	frequency of dialysis session per week	●	●		●	●	●	●	●	●	●	●	●	●	●	●	○	○	○
		dialysis time per session (min)	●	●		●	●	●	●	●	●	●	●	●	●	●	●	○	○	○
		day of week on dialysis				●														
		dialysis time on each day of week				●														
		the day of week when blood test was done				●														
	dialysis membrane	dialyzer membrane material	●		○						●		●							○
		surface area of dialyzer membrane (m²)	●		○						●		●							○
	blood flow rate	blood flow rate (mL/min)				●				●	●	●				●	●	●	○	○
	dialysis fluid	calcium concentration of dialysis fluid (mEq/L)				●	○						●							
		dialysis fluid flow rate (mL/min)				○							●							
		name of dialysis fluid				○							●							
	anticoagulant	anticoagulants for dialysis				●														
		total amount of anticoagulant per session				○														
	blood access	vascular access at the end of the year							●		○									○

Patient Survey

			00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17
patient status	physical data	body height (cm)	○	○	●	●	●	○	●	●	●	●	●	●	●	●	●	○	○	○
		pre- and post-dialysis body weight (kg)	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○
	uremic toxin	pre- and post-dialysis serum urea nitrogen (UN) concentration (mg/dL)	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○
		pre- and post-dialysis serum creatinine concentration (mg/dL)	●	●	●	●		○	●	●	●	●	●	●	●	●	●	○	○	○
		pre-dialysis serum beta$_2$-microgloblin concentration (mg/L)									●		●							○
		post-dialysis serum beta$_2$-microgloblin concentration (mg/L)									○		●							○
	uric acid	pre-dialysis serum uric acid concentration (mg/dL)												●						
		use of drug for hyperuricemia (y/n)												●						
		history of gout attack (y/n)												●						
	protein	pre-dialysis serum albumin concentration (g/dL)	○	○	●	●	●	○	●	●	●	●	●	●	●	●	●	○	○	○
		post-dialysis serum albumin concentration (g/dL)									○									
	sodium	pre- and post-dialysis serum sodium concentration (mEq/L)									●									
	potassium	pre- and post-dialysis serum potassium concentration (mEq/L)									●									
	chloride	pre- and post-dialysis serum chloride concentration (mEq/L)									○									
	magnesium	pre-dialysis serum magnesium concentration (mg/dL)								●										
	lipid	pre-dialysis serum total cholesterol concentration (mg/dL)	○			●			●		●			●	○	○	○	○	○	○
		pre-dialysis serum HDL-cholesterol concentration (mg/dL)	○			●								●	○	○	○	○	○	○
		pre-dialysis serum tryglyceride concentration (mg/dL)				●														
		use of drug for hyperlipidemia (y/n)												●						
		time between preceding meal and blood sampling (hr)				●														
	diabetes	pre-dialysis HbA1c (%)	○													○				
		pre-dialysis glycoalbumin (%)														○				
		use of insulin (y/n)														○				
		use of DPP-4 inhibitor (y/n)														○				
		use of the other prescription drug for diabetes (y/n)														○				
		history of diabetes (y/n)												●		●	●	○	○	○
	acid-base balance	pre-dialysis serum pH	○								○									
		post-dialysis serum pH									○									
		pre-dialysis serum HCO$_3^-$ concntration (mg/dL)					○				●									
		post-dialysis serum HCO$_3^-$ concentration (mg/dL)									○									
	inflammation	pre-dialysis serum C-reactive protein (CRP) concentration (mg/dL)				●	●	○		●	●	●	●	●	●	●	●	○	○	○
	dialysis amyloidosis	surgical history for carpal tunnel syndrome (y/n)										●	●							○
hepatitis	liver function	pre-dialysis serum ALT (IU/L)	○																	
	hapatitis virus marker	HBsAb	○	○					●	●										
		HBsAg	○	○					●	●										
		past history of Hepatitis B vaccination (y/n)	○	○																
		HBsAg/HBsAb	○	○																
		HCVAb	○	○	●	●			●	●										
		HCV-RNA			●	●			●	●										
	HCC/LC	history of hepatocellular carcinoma (HCC) / liver cirrhosis (LC) (y/n)	○																	
smoking	smoking habit	present smoking habit (y/n)	○	○										●	●	●	●	○	○	○
		number of cigarretts per day	○	○																
insurance of the elderly care and activity	insurance of the elderly	status of having the elderly care insurance			●															
		status of using the elderly care insurance			●															
	rehabilitation in society	social rehabilitation status			●															
	physical activity	performance status			●							●	●							
		presence of dementia (y/n)										●	●							
		main residence										●	●							
hospitalization	hospitalization	history of hospitalization in a year (y/n)																		○
		reason for hospitalization																		○

Category	Subcategory	Item	00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17
cardiovascular disease	skin itchiness	presence of skin itchiness (y/n)	●																	
	cardiovascular disease	history of myocardial infarction (2007-ischemic heart disease) (y/n)	○	○	○	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○
		history of brain hemorrhage (y/n)	○	○	○	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○
		history of brain infarction (y/n)	○	○	○	●	●	●	●	●	●	●	●	●	●	●	●	○	○	○
		presence of limb amputation (y/n)	○	○		●	●	●	●	●	●	●	●	●	●	●	●	○	○	○
		history of bypass surgery for peripheral aratery disease (PAD) (y/n)	○																	
		history of artificial blood vessel replacement surgery (y/n)	○																	
		history of blood vessel baloon dilatation (y/n)	○																	
		history of stent graft implantation to peripheral artery (y/n)	○																	
		history of coronary artery bypass graft operation (CABG) (y/n)	○	○																
		history of percutaneous transluminal coronary angioplasty (PTCA) (y/n)	○	○																
		history of coronary artery stenting (y/n)	○	○																
		blindness due to diabetic retinopathy or retinal circulatory disorder (y/n)	○	○																
blood pressure	blood pressure	pre-dialysis blood pressure (systolic/diastolic) (mmHg)	○	●				●							●	●	●	○	○	○
		pre-dialysis pulse rate (beat/min)						●							●	●	●	○	○	○
		post-dialysis blood pressure (systolic/diastolic) (mmHg)	○	●				●												
		post-dialysis pulse rate (beat/min)						●												
		lowest blood pressure during dialysis session (mmHg)		●				●												
		pulse rate at lowest blood pressure during dialysis session (beat/min)						●												
		history of hypertension (y/n)												●						
	hypotension therapy	vasopressor before or during dialysis session (y/n)		●																
		treatment method for hypotension		●																
		use of oral vasopressor agent (y/n)						●												
		infusion of saline (y/n)						●												
		use of high concentration NaCl (y/n)						●												
		use of high concentration glycerin (y/n)						●												
		low temperature dialysis (y/n)						●												
		use of intravenous vasopressor agent (y/n)						●												
	antihypertensive agent	use of antihypertensive agent (y/n)		●																
		use of oral antihypertensive agent (y/n)	○												●	●	●	○	○	○
		calcium antagonist (y/n)						●												
		angiotensin coverting enzyme (ACE) inhibitor (y/n)						●												
		angiotensin II receptor blocker (ARB) (y/n)						●												
		the other antihypertensive agents (y/n)						●												
CKD-MBD	CKD-MBD	pre-dialysis serum calcium concentration (mg/dL)	●			●	●		●	●	○	●	●	●	●	●	●	○	○	○
		post-dialysis serum calcium concentration (mg/dL)									○									
		pre-dialysis serum phosphate concentration (mg/dL)	●			●	●		●	●	●	●	●	●	●	●	●	○	○	○
		post-dialysis serum phosphate concentration (mg/dL)									○									
		pre-dialysis serum alkaline phosphatase (ALP) concentration										●								
		pre-dialysis serum intact parathyroid hormone (PTH) concentration (pg/mL)	●			●	●		●	●		(↓)	(↓)	(↓)	(↓)	(↓)	(↓)	(↓)	(↓)	(↓)
		method/value for serum PTH concentration (intact-, whole-, HS-) (pg/mL)										●								
		method/value for serum PTH concentration (intact-, whole-) (pg/mL)										●	●	●	●	●	●	○	○	○

Category	Subcategory	Item	00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17
CKD-MBD	phosphate binder	use of sevelamer hydrochloride (y/n)										●								
		dose of sevelamer hydrochloride (mg/day)					●													
		use of aluminum hydroxide (y/n)					●													
		use of calcium carbonate (y/n)	○									●								
		dose of calcium carbonate (g/day)	○				●													
		use of lanthanum carbonate hydrate (y/n)										●								
		use of the other phosphate binders (y/n)					●					●								
	vitamin D	current PD treatment (y/n)	○																	
		use of vitamin D receptor activator (VDRA) (y/n)	○																	
		dose of VDRA (μg/day)						●				●								
		use of oral VDRA (y/n)						●												
		dose of oral VDRA (μg/day)						●				●								
		use of intravenous VDRA (y/n)						●												
		dose of intravenous VDRA (μg/day)										●								
	cinacalcet	use of cinacalcet hydrochloride (y/n)						●												
	surgery	history (number) of percutaneous ethanol injection therapy (PEIT) (y/n)						●												
		history of parathyroidectomy (PTX) (y/n)								●		●								
		history of PEIT (y/n)								●		●								
	bone fracture	history of proximal thighbone (Femur) fracture (hip bone fracture until 2014) (y/n)								●	●	●	●	●	●	●	●	○	○	○
anemia	Hct/Hb	pre-dialysis hematocrit (%)	○	○	○				●											
		pre-dialysis hemoglobin (Hb) concentration (g/dL)				○	●	●	●	●	●	●	●	●	●	●	●	○	○	○
		post-dialysis hemoglobin (Hb) concentration (g/dL)								○										
	iron metabolism	pre-dialysis serum iron concentration (μg/dL)					○	●	●				○							
		pre-dialysis serum total iron-binding capacity (μg/dL)					○	●	●				○							
		pre-dialysis serum ferritin concentration					○	●	●				○							
	anemia treatment	use of erythropoiesis stimulating agents (ESA)	○	○	○															
		type of ESA											○							
		dose of ESA	○	○	○		○	●					○							
		use of anabolic steroids (y/n)	○																	
peritoneal dialysis (PD)	peritoneal dialysis (PD)	current PD treatment (y/n)						●												
		the month of initiating PD therapy						●												
		number of days performing PD in a week						●												
		type of CAPD treatment						●												
		number of months performing PD in a year													○	○	○	○	○	○
		undergoing peritoneal equilibration test (PET) (y/n)												○	○	○	○	○	○	○
		four-hour creatinine concentration dialysate/plasma ratio in PET (PET Cr D/P)						●	●					○	○	○	○	○	○	○
		type of PD fluid						●						○	○	○	○	○	○	○
		total volume of PD fluid per day (L/day)						●						○	○	○	○	○	○	○
		residual kidney function (urine volume per day) (mL/day)												○	○	○	○	○	○	○
		mean ultrafiltration (UF) volume per day (mL/day)						●						○	○	○	○	○	○	○
		KT/V by residual kidney (residual kidney Kt/V)												○	○	○	○	○	○	○
		Kt/V by PD (PD KT/V)												○	○	○	○	○	○	○
		use of automated peritoneal dialysis (APD) machine (y/n)													○	○	○	○	○	○
		time of PD treatment per day (hr)													○	○	○	○	○	○
		changing maneuver of PD fluids													○	○	○	○	○	○
		history (number) of peritonitis in a year						●						○	○	○	○	○	○	○
		history (number) of exit-site infections in a year													○	○	○	○	○	○
		history of encapsulating peritoneal sclerosis (EPS) (y/n)						●				○	●	●	●	●	●	○	○	○
		month of withdrawal from PD						●	●											
		reason for withdrawal from PD						●	●											

			00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17
survey at the first dialysis session	clinical findings at the first dialysis session	the year of first visit to the incident dialysis hospital							O	O										
		the month of first visit to the incident dialysis hospital							O	O										
		pre-dialysis body weight in the first dialysis session (kg)							O	O										
		pre-dialysis serum urea nitrogen in the first dialysis session (mg/dL)							O	O										
		pre-dialysis serum creatinine in the first dialysis session (mg/dL)							O	O										
		method for measuring pre-dialysis serum creatinine in the first dialysis session							O	O										
		pre-dialysis serum albumin in the first dialysis session (g/dL)							O	O										
		pre-dialysis serum CRP in the first dialysis session (mg/dL)							O	O										
		pre-dialysis hemoglobin in the first dialysis session (g/dL)							O	O										
		pre-dialysis serum calcium in the first dialysis session (mg/dL)							O	O										
		pre-dialysis serum phosphate in the first dialysis session (mg/dL)							O	O										
		pre-dialysis serum HCO_3^- in the first dialysis session (mg/dL)							O	O										
		pre-dialysis systolic blood pressure in the first dialysis session (mmHg)							O	O										
		pre-dialysis diastolic blood pressure in the first dialysis session (mmHg)							O	O										
		the year of the first vascular access operation	O						O	O										
		the month of the first vascular access operation	O						O	O										
		type of the first vascular access	O						O	O										
	complications at the first dialysis session	history of myocardial infarction (y/n)							O	O										
		history of cogestive heart disease (y/n)							O	O										
		history of limb (major) amputation, arteriosclerosis obliterans (ASO), or aortic aneurysm 6cm<= (y/n)							O	O										
		history of cerebral infarction and/or TIA (y/n)							O	O										
		dementia (y/n)							O	O										
		chronic lung disease (y/n)							O	O										
		collagen disease (y/n)							O	O										
		peptic ulcer (y/n)								O										
		chronic liver disease without portal hypertension and/or chronic hepatitis (y/n)							O	O										
		diabetes (without organ failure, excluding only diet patients) (y/n)							O	O										
		hemiplegia (y/n)							O	O										
		diabetes(advanced retinopathy, neuropathy, and Brittle type DM) (y/n)							O	O										
		malignant tumor (without metastasis, excluding patients over 5 years after diagnosis) (y/n)							O	O										
		leukemia (acute, chronic) (y/n)							O	O										
		lymphoma (y/n)							O	O										
		moderate/advanced liver disease (y/n)							O	O										
		metastatic malignant tumor (y/n)							O	O										
		AIDS (y/n)							O	O										
	symptoms at the first dialysis session	hypervolemia (systemic edema, advanced hypoproteinemia, and/or lung edema) (y/n)							O	O										
		abnormal body fluid (uncontrol electrolyte, abnormal acid-base balance) (y/n)							O	O										
		digestive symptom (nausea, vomiting, appetite loss, diarrhea, etc.) (y/n)							O	O										
		cardiovascular symptom (advanced hypertension, heart failure, pericarditis) (y/n)							O	O										
		neurological symptom (central/peripheral nerve disorder, mental disorder) (y/n)							O	O										
		blood abnormality (advanced anemia symptom, bleeding tendency) (y/n)							O	O										
		visual disturbance (uremic retinopathy, diabetic retinopathy) (y/n)							O	O										
		accident value of activity of daily life (ADL)							O	O										